Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
9
self-reported 2–10 band
Founded
2017
9 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
GLYTHERIX LTD
ABN66621291996
Legal entities
Show as table · GlyTherix Ltd: 1 registry entity
| GLYTHERIX LTD | ABN 66621291996 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
GlyTherix Ltd, is a targeted radiotherapy company with a clinical stage antibody product, Miltuximab®, showing an excellent safety profile in high unmet need cancers. Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue.
There is a large addressable market in the USA and Europe of US$21.7 billion per annum. The company has a strong proprietary and intellectual property position covering the Miltuximab® antibody, epitope and the antigen. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope.
Miltuximab® precisely delivers targeted radiation to cancer cells. The company chelates a low energy 89Zirconium isotope to the antibody for diagnostic imaging. Image positive patients can then receive a dose of Miltuximab® that is chelated to the high energy isotope 177Lutetium resulting in a cell destroying dose directly at the site of the cancer. GlyTherix also has a pre-clinical program underway investigating the use of alpha particles, ie 225Actinium and 212Lead.
GlyTherix has completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse. events. Miltuximab® will be used in both the Phase Ib and US Phase 2 trials as an antibody theranostic.
The company has entered an exclusive manufacturing, supply & distribution agreements with reliable isotope suppliers ANSTO and Cyclowest Holdings, both highly regarded nuclear medicine companies in Australia. Agreements with US based CDMOs and isotope suppliers for our planned US trials are also in place.
GlyTherix has a strong management and research team and a highly experienced clinical advisory panel who have been intimately involved in commercialisation of targeted radiotherapies that are marketed in the US and elsewhere.
Specialties
All 4 specialties
- immuno-oncology company
- therapeutics for solid tumors
- targeted treatment of prostate
- bladder and pancreas cancers
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU3 Innovation Rd; Level 1; Macquarie Park, New South Wales 2113Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
3 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under GlyTherix Ltd?
One New South Wales entity on the ABR: GLYTHERIX LTD (ABN 66 621 291 996), high confidence.
How many people work at GlyTherix Ltd?
9 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does GlyTherix Ltd have offices?
One address on record, Australia only. Primary: 3 Innovation Rd, Level 1, Macquarie Park, New South Wales 2113.
Has GlyTherix Ltd raised funding?
None linked to this brand.
What does GlyTherix Ltd list as its specialties?
Four tags on the brand's own list, among them immuno-oncology company, therapeutics for solid tumors and targeted treatment of prostate.
Which companies are listed alongside GlyTherix Ltd?
3 profiles list GlyTherix Ltd as a peer — 50th percentile in Biotechnology. It lists ten peers of its own. Minomic International Ltd and Cyclowest list it back.